The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China

• DOI: 10.3389/fpubh.2024.1333487
• Publication Date: 2024-04-15T16:46:07Z
• Authors: Zhanjing Dai; Jiayi Xu; Feng Chang; Wanxin Zhou; Ting Ren; Jiaxin Qiu; Yun Lu; Yuqiong Lu
• Keywords: Alectinib; ALK inhibitor

Background Iruplinalkib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine inhibitor (TKI) with efficacy in patients ALK-positive crizotinib-resistant advanced non-small cell lung cancer (NSCLC), which independently developed by Chinese pharmaceutical company. This study examined the cost-effectiveness of iruplinalkib versus alectinib healthcare setting. Methods A partitioned survival model was to project economic and health outcomes. Efficacy derived using unanchored matching-adjusted indirect comparison (MAIC). Cost utility values were obtained from literature experts’ opinions. Deterministic probabilistic sensitivity analyses (PSA) carried out evaluate model’s robustness. Results Treatment resulted gain 0.843 quality-adjusted life years (QALYs) incremental costs $20,493.27, resulting an ratio (ICER) $24,313.95/QALY. Parameters related relative drug main drivers From PSA, had 90% probability being cost-effective at willingness-to-pay threshold $37,863.56/QALY. Conclusion Compared alectinib, therapy for NSCLC.